Abstract
We present a new strategy for systematic identification of phosphotyrosine (pTyr) by affinity purification mass spectrometry (AP-MS) using a Src homology 2 (SH2)-domain-derived pTyr superbinder as the affinity reagent. The superbinder allows for markedly deeper coverage of the Tyr phosphoproteome than anti-pTyr antibodies when an optimal amount is used. We identified ∼20,000 distinct phosphotyrosyl peptides and >10,000 pTyr sites, of which 36% were 'novel', from nine human cell lines using the superbinder approach. Tyrosine kinases, SH2 domains and phosphotyrosine phosphatases were preferably phosphorylated, suggesting that the toolkit of kinase signaling is subject to intensive regulation by phosphorylation. Cell-type-specific global kinase activation patterns inferred from label-free quantitation of Tyr phosphorylation guided the design of experiments to inhibit cancer cell proliferation by blocking the highly activated tyrosine kinases. Therefore, the superbinder is a highly efficient and cost-effective alternative to conventional antibodies for systematic and quantitative characterization of the tyrosine phosphoproteome under normal or pathological conditions.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Proteome and phosphoproteome signatures of recurrence for HPV+ head and neck squamous cell carcinoma
Communications Medicine Open Access 30 July 2022
-
Low molecular weight protein phosphatase APH mediates tyrosine dephosphorylation and ABA response in Arabidopsis.
Stress Biology Open Access 18 May 2022
-
Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma
Nature Communications Open Access 16 September 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout





References
Sharma, K. et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 8, 1583–1594 (2014).
Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
Wilhelm, M. et al. Mass-spectrometry-based draft of the human proteome. Nature 509, 582–587 (2014).
Kim, M.S. et al. A draft map of the human proteome. Nature 509, 575–581 (2014).
Li, L. et al. Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nat. Commun. 5, 5469 (2014).
Zhou, H. et al. Robust phosphoproteome enrichment using monodisperse microsphere-based immobilized titanium (IV) ion affinity chromatography. Nat. Protoc. 8, 461–480 (2013).
de Graaf, E.L., Giansanti, P., Altelaar, A.F. & Heck, A.J. Single-step enrichment by Ti4+-IMAC and label-free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal resolution. Mol. Cell. Proteomics 13, 2426–2434 (2014).
Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203 (2007).
Zhang, Y. et al. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell. Proteomics 4, 1240–1250 (2005).
Tinti, M. et al. The 4G10, pY20 and p-TYR-100 antibody specificity: profiling by peptide microarrays. Nat. Biotechnol. 29, 571–577 (2012).
Jones, R.B., Gordus, A., Krall, J.A. & MacBeath, G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439, 168–174 (2006).
Kaneko, T. et al. Superbinder SH2 domains act as antagonists of cell signaling. Sci. Signal. 5, ra68 (2012).
Rush, J. et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23, 94–101 (2005).
Findlay, G.M. et al. Interaction domains of Sos1/Grb2 are finely tuned for cooperative control of embryonic stem cell fate. Cell 152, 1008–1020 (2013).
Huyer, G. et al. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J. Biol. Chem. 272, 843–851 (1997).
Huang, H. et al. Defining the specificity space of the human SRC homology 2 domain. Mol. Cell. Proteomics 7, 768–784 (2008).
Boersema, P.J., Raijmakers, R., Lemeer, S., Mohammed, S. & Heck, A.J. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat. Protoc. 4, 484–494 (2009).
Subik, K. et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl.) 4, 35–41 (2010).
Matlock, M.K., Holehouse, A.S. & Naegle, K.M. ProteomeScout: a repository and analysis resource for post-translational modifications and proteins. Nucleic Acids Res. 43, D521–D530 (2015).
Hornbeck, P.V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40, D261–D270 (2012).
Lu, C.T. et al. DbPTM 3.0: an informative resource for investigating substrate site specificity and functional association of protein post-translational modifications. Nucleic Acids Res. 41, D295–D305 (2013).
UniProt Consortium. Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res. 42, D191–D198 (2014).
Geiger, T., Wehner, A., Schaab, C., Cox, J. & Mann, M. Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol. Cell. Proteomics 11, M111.014050 (2012).
Stokes, M.P. et al. Complementary PTM Profiling of Drug Response in Human Gastric Carcinoma by Immunoaffinity and IMAC Methods with Total Proteome Analysis. Proteomes 3, 160–183 (2015).
Hubbard, S.R., Mohammadi, M. & Schlessinger, J. Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 273, 11987–11990 (1998).
Qian, X. et al. The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. Cancer Cell 16, 246–258 (2009).
Jin, L.L. et al. Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity. Mol. Cell. Proteomics 14, 695–706 (2015).
Andersen, J.N. et al. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell. Biol. 21, 7117–7136 (2001).
Mitra, S., Beach, C., Feng, G.S. & Plattner, R. SHP-2 is a novel target of Abl kinases during cell proliferation. J. Cell Sci. 121, 3335–3346 (2008).
Feng, J. et al. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17, 2497–2501 (1997).
Zhang, J., Billingsley, M.L., Kincaid, R.L. & Siraganian, R.P. Phosphorylation of Syk activation loop tyrosines is essential for Syk function. An in vivo study using a specific anti-Syk activation loop phosphotyrosine antibody. J. Biol. Chem. 275, 35442–35447 (2000).
Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938–1942 (2000).
Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275–282 (2002).
Xie, Y., Pendergast, A.M. & Hung, M.C. Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. J. Biol. Chem. 270, 30717–30724 (1995).
Sepp-Lorenzino, L. et al. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene 12, 1679–1687 (1996).
Dey, B.R., Frick, K., Lopaczynski, W., Nissley, S.P. & Furlanetto, R.W. Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10. Mol. Endocrinol. 10, 631–641 (1996).
Tartare-Deckert, S., Sawka-Verhelle, D., Murdaca, J. & Van Obberghen, E. Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system. J. Biol. Chem. 270, 23456–23460 (1995).
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
Takeuchi, K. & Ito, F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol. Pharm. Bull. 34, 1774–1780 (2011).
Levitzki, A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu. Rev. Pharmacol. Toxicol. 53, 161–185 (2013).
Zaman, N. et al. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. Cell Rep. 5, 216–223 (2013).
Esteva, F.J., Yu, D., Hung, M.C. & Hortobagyi, G.N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7, 98–107 (2010).
Sabbatini, P. et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 8, 2811–2820 (2009).
Kim, H.G. et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem. Biol. 8, 2145–2150 (2013).
Zhang, S. et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 17, 461–469 (2011).
Lee, M.J. et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780–794 (2012).
Hochgräfe, F. et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res. 70, 9391–9401 (2010).
Lemmon, M.A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010).
Krause, D.S. & Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172–187 (2005).
Debnath, J., Muthuswamy, S.K. & Brugge, J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256–268 (2003).
Boersema, P.J. et al. In-depth qualitative and quantitative profiling of tyrosine phosphorylation using a combination of phosphopeptide immunoaffinity purification and stable isotope dimethyl labeling. Mol. Cell. Proteomics 9, 84–99 (2010).
Zhou, H. et al. Specific phosphopeptide enrichment with immobilized titanium ion affinity chromatography adsorbent for phosphoproteome analysis. J. Proteome Res. 7, 3957–3967 (2008).
Wang, F. et al. A fully automated system with online sample loading, isotope dimethyl labeling and multidimensional separation for high-throughput quantitative proteome analysis. Anal. Chem. 82, 3007–3015 (2010).
Olsen, J.V. et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635–648 (2006).
Acknowledgements
This work was supported, in part, by funds from the China State Key Basic Research Program Grants (2012CB910101 and 2016YFA0501402 to M.Y. and 2013CB911202 to H.Z.), the National Natural Science Foundation of China (21235006, 21321064 and 21535008 to H.Z., and 81361128015 to M.Y. and S.S.-C.L.), the Canadian Cancer Society (to S.S.-C.L.), the Canadian Institute of Health Research (to S.S.-C.L. and M.Y.) and the Ontario Research Fund (to S.S.-C.L.). L.L. is a recipient of “Distinguished Expert of Overseas Tai Shan Scholar”. M.Y. is a recipient of the National Science Fund of China for Distinguished Young Scholars (21525524). S.S.-C.L. holds a Canadian Research Chair in Functional Genomics and Cellular Proteomics.
Author information
Authors and Affiliations
Contributions
S.S.-C.L., H.Z., M.Y. and M.D. conceived and designed the project. Y.B. and M.D. carried out the pTyr enrichment experiments and MS analysis under the supervision of H.Z., M.Y. and S.S.-C.L. L.L., M.Y., Y.B., M.D., K.C., T.K. and S.S.-C.L. analyzed the data. X.L., Y.W. and X.C. performed the cellular and biochemical experiments with input from S.S.-C.L. and D.L. C.V. and H.L. prepared the superbinder reagents. S.S.-C.L., L.L. and M.Y. wrote the manuscript with input from H.Z., M.D., Y.B. and D.L.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Results, Supplementary Tables 1–6 and Supplementary Figures 1–19. (PDF 9135 kb)
Supplementary Dataset
Supplementary Datasets 1–8. (XLSX 41064 kb)
Rights and permissions
About this article
Cite this article
Bian, Y., Li, L., Dong, M. et al. Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine superbinder. Nat Chem Biol 12, 959–966 (2016). https://doi.org/10.1038/nchembio.2178
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.2178
This article is cited by
-
Pilot investigation of magnetic nanoparticle–based immobilized metal affinity chromatography for efficient enrichment of phosphoproteoforms for mass spectrometry–based top-down proteomics
Analytical and Bioanalytical Chemistry (2023)
-
Proteome and phosphoproteome signatures of recurrence for HPV+ head and neck squamous cell carcinoma
Communications Medicine (2022)
-
Low molecular weight protein phosphatase APH mediates tyrosine dephosphorylation and ABA response in Arabidopsis.
Stress Biology (2022)
-
Identification and development of a glucaric acid biosensor in Saccharomyces cerevisiae
Systems Microbiology and Biomanufacturing (2022)
-
Current advance in biological production of short-chain organic acid
Applied Microbiology and Biotechnology (2020)